TEVA
TEVA
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
4
$27.94M
Total Volume
$27.94M
4 transactions
Net Activity
$27.94M
Net selling
Sentiment Rating
Heavy DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Mignone Roberto
Dir
$14.36M total
Francis Richard D
Pres, CEO
$10.56M total
Sabag Mark
See "Remarks"
$1.93M total
Bergwerk Dov
Interim Cheif Legal Officer
$1.10M total
Quick Actions
TEVA has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. TEVA ranks #121 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at TEVA (TEVA) engaged in a total of 4 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 4 were sales. The total volume of insider trading reached $27.94M.
The net insider activity for TEVA shows a net selling bias of $27.94M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Mignone Roberto (Dir), who traded 367.6K shares valued at $14.36M on Sep 18, 2026.
TEVA Stock Quote Price and Forecast
Teva falls as R&D head exits amid shift to innovative medicines
Teva settles US states' drug price-fixing case
Teva’s CEO has three conference appearances scheduled for Nov. 30 and Dec. 1
Teva Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Teva (TEVA)
Teva (TEVA) Stock Still Looks Like A Bargain On Cash Flow
FAQs About TEVA Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for TEVA.